"just one safety trial" said stoney...
On January 2, 2019, we announced the dosing of the first subject in a randomized, placebo-controlled phase 1 clinical trial to evaluate intravenous galidesivir in healthy volunteers. The main goals of this trial are to evaluate the safety, tolerability and pharmacokinetics of escalating intravenous doses of galidesivir in healthy subjects. Up to four single-dose cohorts will be evaluated with a total of up to 32 volunteers participating.
that's from the last 10k. should be done by now eh?
Coronavirus In China: Over 200 Cases, Human-To-Human Transmission